|
FAES FARMA SA is a pharmaceutical company that researches, produces, and markets prescription medicines, healthcare products, and animal nutrition solutions. The company operates through two main business segments: Pharma & Health Care, which includes prescription drugs and over-the-counter products for treating allergic, gastrointestinal, immune, and pain-related conditions, and Farm Faes, which provides nutritional solutions and feed for animal production. Key products include Bilastina (marketed as Bilaxten), a second-generation antihistamine, and Hidrosmina (marketed as Venosmil). The company serves markets in Iberia, Latin America, and Africa-Middle East, with subsidiaries in Portugal, Italy, Mexico, Guatemala, Colombia, Chile, Peru, Ecuador, Nigeria, and the United Arab Emirates. FAES FARMA SA was founded in 1933 and has expanded its portfolio through acquisitions such as Laboratorios Vitoria, Iquinosa, Ingaso Farm, Tecnovit, Capselos, Laboratorios Diafarm, BCN Medical, Global Farma, and Novosci. Summarised from the company's own disclosures, fiscal year ended Dec 2025 |
Industry Drug Manufacturers - General | Homepage faesfarma.com |
| Sector Healthcare | IR page faesfarma.com/accionistas-e-inversores | |
|
Tags
antihistamines, animal nutrition, prescription medicines, over-the-counter products, gastroenterology, immunology, pain management, porcine feed, veterinary health, Bilaxten, Venosmil, Hidrosmina, Bilastina, Farm Faes, Laboratorios Vitoria, Iquinosa, Ingaso Farm, Tecnovit, Capselos, Laboratorios Diafarm, BCN Medical, Global Farma, Novosci, Hidroferol, Alergical, Zyloric, Dezacor, Rossilan, Claversal, Pankreoflat, Tanakene
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | — |
| P/E | — |
| P/BV | — |
| P/S | — |
| P/OCF | — |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 10.8% |
| ROI | 10.7% |
| ROIC | 11.2% |
| Profit margin | 13.0% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 38.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 610.464M | 493.647M | 451.168M | 438.754M | 398.557M | 380.24M | 357.398M | 324.312M | 274.576M | 228.635M | 204.724M | 191.742M | 180.394M | 176.109M | 190.224M | 202.507M |
| Free cash flow | 62.385M | 81.654M | 5.206M | 31.572M | 28.155M | 58.278M | 50.611M | — | — | — | — | — | — | — | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpPrompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.